Selective publications:

Leucine-rich repeat kinase 2 impairs the release sites of Parkinson's disease vulnerable dopamine axons. Chen C, He Q, Tombesi G, Napier E, Jaconelli M, Moreno-Ramos OA, Serio H, Naaldijk Y, Promes V, Schneeweis A, Quinn K, Nasios C, Greggio E, Kozorovitskiy Y, Arango D, Khan AR, Alessi DR, Dombeck DA, Hilfiker S, Awatramani R, Parisiadou L. bioRxiv. 2025 doi: 10.1101/2025.08.28.672006. Under Review Nature Neuroscience

Molecular and spatial transcriptomic classification of midbrain dopamine neurons and their alterations in a LRRK2G2019S model of Parkinson's disease Gaertner Z, Oram C, Schneeweis A, Schonfeld E, Bolduc C, Chen C, Dombeck D, Parisiadou L, Poulin JF, Awatramani R. Elife. 2025. 13:RP101035 doi: 10.7554/eLife.101035.

LRRK2 mediates haloperidol-induced changes in indirect pathway striatal projection neurons. Chen C, Masotti M, Shepard N, Promes V, Tombesi G, Arango D, Manzoni C, Greggio E, Hilfiker S, Kozorovitskiy Y, Parisiadou L. Molecular Psychiatry. 2025. doi: 10.1038/s41380-025-03030-z

Pathogenic LRRK2 causes age-dependent and region-specific deficits in ciliation, innervation and viability of cholinergic neurons. Brahmia B, Naaldijk Y, Sarkar P, Parisiadou L, Hilfiker S. eLife, 2024. doi:10.7554/eLife.101135.1

LRRK2 regulates dendritic spine dynamics through interaction with postsynaptic actin cytoskeleton. Tombesi G, Chen C, Favetta G, Plotegher N, Sevegnani M, Marte A, Battisti I, Civiero L, Onofri F, Piccoli G, Arrigoni G, Manzoni C, Parisiadou L, Greggio E. eLife, 2024. doi.org/10.7554/eLife.95987.1

R1441C and G2019S LRRK2 knockin mice have distinct striatal molecular, physiological, and behavioral alterations. Xenias HS, Chen C, Kang S, Cherian S, Situ X, Shanmugasundaram B, Liu G, Scesa G, Chan CS, Parisiadou L. Communications Biology. 2022 Nov 10;5(1):1211. doi: 10.1038/s42003-022-04136-8.

Closing the structure-to-function gap for LRRK2. Tokars V, Chen C, Parisiadou L. Trends in Biochemical Sciences. 2022 47(3):187-188

Pathway-specific deregulation of striatal excitatory synapses in LRRK2 mutations. Chen C, Soto N, Kang S, Kozorovitskiy Y, Parisiadou L. eLife, 2020 Oct 2;9:e58997. doi: 10.7554/eLife.58997.

Selective expression of Parkinson's disease-related Leucine-rich repeat kinase 2 G2019S missense mutation in midbrain dopaminergic neurons impairs dopamine release and dopaminergic gene expression. Liu G, Sgobio C, Gu X, Sun L, Lin X, Yu J, Parisiadou L, Xie C, Sastry N, Ding J, Lohr KM, Miller GW, Mateo Y, Lovinger DM, Cai H. Hum Mol Genet. 2015 Sep 15;24(18):5299-312. doi: 10.1093/hmg/ddv249. PubMed. PDF. 

Leucine-rich repeat kinase 2 regulates Sec16A at ER exit sites to allow ER-Golgi export. Cho HJ, Yu J, Xie C, Rudrabhatla P, Chen X, Wu J, Parisiadou L, Liu G, Sun L, Ma B, Ding J, Liu Z, Cai H. EMBO J. 2014. Oct 16;33(20):2314-31. doi: 10.15252/embj.201487807. PubMed. PDF.

A calcineurin- and NFAT-dependent pathway is involved in α-synuclein-induced degeneration of midbrain dopaminergic neurons. Luo J, Sun L, Lin X, Liu G, Yu J, Parisiadou L, Xie C, Ding J, Cai H. Hum Mol Genet. 2014 Dec 15;23(24):6567-74. doi: 10.1093/hmg/ddu377. PubMed. PDF.

LRRK2 regulates synaptogenesis and dopamine receptor activation through modulation of PKA activity. Parisiadou L#, Yu J, Sgobio C, Xie C, Liu G, Sun L, Gu XL, Lin X, Crowley NA, Lovinger DM, Cai H#. Nature Neuroscience 2014 Mar;17(3):367-76. doi: 10.1038/nn.3636. Recommended by F1000.  PubMed. PDF. 

MicroRNA-205 regulates the expression of Parkinson's disease-related leucine-rich repeat kinase 2 protein. Cho HJ, Liu G, Jin SM, Parisiadou L, Xie C, Yu J, Sun L, Ma B, Ding J, Vancraenenbroeck R, Lobbestael E, Baekelandt V, Taymans JM, He P, Troncoso JC, Shen Y, Cai H. Hum Mol Genet. 2013 Feb 1;22(3):608-20. doi: 10.1093/hmg/dds470. PubMed. PDF.

Conditional expression of Parkinson's disease-related mutant α-synuclein in the midbrain dopaminergic neurons causes progressive neurodegeneration and degradation of transcription factor nuclear receptor related 1. Lin X*, Parisiadou L*, Sgobio C, Liu G, Yu J, Sun L, Shim H, Gu XL, Luo J, Long CX, Ding J, Mateo Y, Sullivan PH, Wu LG, Goldstein DS, Lovinger D, Cai H. Journal of Neuroscience. 2012 Jul 4;32(27):9248-64. doi: 10.1523/JNEUROSCI.1731-12.2012.Recommended by F1000. PubMed. PDF.

LRRK2 function on actin and microtubule dynamics in Parkinson’s disease. Parisiadou L, Cai H. Commun Integr Biol. 2010 Sep;3(5):396-400. doi: 10.4161/cib.3.5.12286. PubMed. PDF.

Leucine-rich repeat kinase 2 regulates the progression of neuropathology induced by Parkinson's-disease-related mutant alpha-synuclein. Lin X*, Parisiadou L*, Gu XL, Wang L, Shim H, Sun L, Xie C, Long CX, Yang WJ, Ding J, Chen ZZ, Gallant PE, Tao-Cheng JH, Rudow G, Troncoso JC, Liu Z, Li Z, Cai H. Neuron. 2009 Dec 24;64(6):807-27. doi: 10.1016/j.neuron.2009.11.006. Recommended by F1000. PubMed. PDF.

Phosphorylation of ezrin/radixin/moesin proteins by LRRK2 promotes the rearrangement of actin cytoskeleton in neuronal morphogenesis. Parisiadou L, Xie C, Cho HJ, Lin X, Gu XL, Long CX, Lobbestael E, Baekelandt V, Taymans JM, Sun L, Cai H. Journal of Neuroscience. 2009 Nov 4;29(44):13971-80. doi: 10.1523/JNEUROSCI.3799-09.2009. PubMed. PDF.

For a complete publication list click here